Blood tests to improve risk prediction in cardiogenic shock
Part of Heart & circulation clinical trials.
This study looks at whether adding two blood test markers (neutrophil-lymphocyte ratio and red cell distribution width) to a standard scoring system can better predict recovery or risk in patients with cardiogenic shock. If you are in the hospital with this condition, the results could help doctors understand your outlook more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with cardiogenic shock, which means your heart isn't pumping enough blood.
- You do not have other conditions like an active infection, a chronic inflammatory disease, a blood disorder, cancer, liver disease, or recent blood transfusion.
- You are not on immunosuppressive or steroid therapy.
- You have a complete blood count (a blood test) results from when you were admitted.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people with cardiogenic shock (or very low blood pressure from heart causes) do after treatment in a specialized cardiovascular ICU. It also examines whether care by heart critical-care specialists affects outcomes.
This trial tests whether setting a personalized blood pressure goal for each person in cardiogenic shock improves recovery compared to standard care. It may help if you have severe shock and can be enrolled within the first 24 hours.
This study looks at whether a person’s genetic information (genomics) can help predict outcomes in cardiogenic shock. You may be asked to give consent and provide information during a serious heart-related emergency, usually soon after symptoms start.
This study collects information from people with cardiogenic shock (a condition where the heart cannot pump enough blood for the body) to improve future care. You will not receive any new treatment, but your participation helps doctors understand and manage this condition better.
This trial studies specific body proteins to understand why fluid can leak from blood vessels during dangerous shock after infection or heart problems. If you (or your representative) qualify, your team will collect information and possibly samples to see whether these proteins relate to recovery and treatment response.
This study is a “registry,” meaning it collects health information from people hospitalized with cardiogenic shock. It may help doctors better understand the condition and improve care over time.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.